1. Introduction {#sec1-jcm-08-00623}
===============

The obesity rate has nearly tripled worldwide since 1975, with World Health Organization data indicating that in 2016, 39% of adults were overweight and 13% were obese \[[@B1-jcm-08-00623]\]. In the United States, recent figures indicate that 40% of adults are obese, with the obesity rate in the 40--60 year old age group exceeding 40% \[[@B1-jcm-08-00623]\].

While obesity is a risk factor for metabolic disease, sub cohorts with obesity not complicated by the metabolic syndrome have been described. These so called "metabolically healthy obese" may have reduced risk of type 2 diabetes, cardiovascular disease and all-cause mortality compared with individuals with obesity and the metabolic syndrome \[[@B2-jcm-08-00623]\]. The criteria used to define metabolically healthy obesity (MHO) varies widely across studies. With at least 30 different definitions applied, the prevalence of MHO ranged from 6 to 75% in the obese population \[[@B3-jcm-08-00623]\]. Most studies included blood pressure, high density lipoprotein (HDL) cholesterol, fasting plasma glucose and/or triglyceride in their definition. Less than half included the insulin resistance surrogate homeostatic model assessment of insulin resistance (HOMA-IR), and less than one-third included diabetes \[[@B3-jcm-08-00623]\]. Compared to the use of the metabolic syndrome criteria to sub-categorise obesity, fewer studies have used insulin sensitivity per se (that is, sub-categorisation into insulin-sensitive obesity (Ob~Sen~) and insulin-resistant obesity (Ob~Res~)). Most studies considering insulin resistance used the insulin resistance surrogate homeostatic model assessment of insulin resistance (HOMA-IR) \[[@B3-jcm-08-00623]\]; some smaller cohort studies used the gold-standard hyperinsulinaemic-euglycaemic clamp \[[@B4-jcm-08-00623],[@B5-jcm-08-00623]\].

Despite having a better metabolic health profile compared to the metabolically unhealthy obesity group, longitudinal studies with diabetes and cardiovascular disease endpoints reported that MHO individuals held an intermediate health status, such that they were still worse off than the healthy normal weight individuals \[[@B6-jcm-08-00623]\]. Moreover, recent longitudinal studies have shown that a large proportion of MHO progress to the unhealthy category over time \[[@B7-jcm-08-00623],[@B8-jcm-08-00623],[@B9-jcm-08-00623],[@B10-jcm-08-00623],[@B11-jcm-08-00623],[@B12-jcm-08-00623],[@B13-jcm-08-00623],[@B14-jcm-08-00623]\]. Predictors of loss of metabolic health in MHO include older age \[[@B9-jcm-08-00623],[@B15-jcm-08-00623]\] and poorer cardio-metabolic risk at baseline, including lower HDL \[[@B9-jcm-08-00623],[@B11-jcm-08-00623],[@B12-jcm-08-00623],[@B13-jcm-08-00623]\], higher triglycerides \[[@B11-jcm-08-00623],[@B12-jcm-08-00623],[@B13-jcm-08-00623]\], higher central adiposity \[[@B11-jcm-08-00623],[@B15-jcm-08-00623]\] and insulin resistance \[[@B9-jcm-08-00623],[@B11-jcm-08-00623],[@B12-jcm-08-00623],[@B13-jcm-08-00623]\].

While there have been studies evaluating the stability of the MHO phenotype over time, to our knowledge no study has reported the durability of insulin-sensitivity per se, measured by the gold-standard hyperinsulinaemic-euglycaemic clamp in overweight and obese individuals. Focusing on the change in insulin resistance over time is key to dissecting the mechanism underlying the development of cardio-metabolic disease in individuals at risk. In the present study, we aimed to trace the change in insulin resistance, and to uncover predictors of insulin resistance in older age. The secondary aims were to trace the change in body composition, fat distribution and metabolic markers over time in a well-phenotyped cohort studied approximately 5 years apart.

2. Experimental Section {#sec2-jcm-08-00623}
=======================

2.1. Participants {#sec2dot1-jcm-08-00623}
-----------------

The Insulin Sensitivity in Obesity Study (ISOS) was approved by the St Vincent's Hospital Human Research Ethics Committee and the Garvan Institute of Medical Research Governance Office and registered at [ClinicalTrials.gov](ClinicalTrials.gov) (NCT02017210).

Participants of two previous separate studies performed at the Garvan Institute of Medical Research (Darlinghurst, NSW, Australia) \[[@B16-jcm-08-00623],[@B17-jcm-08-00623]\] were contacted by postal mail to gauge interest in participating in a follow-up study. At the time of these previous studies ("baseline studies"), participants agreed to be contacted in the future for other potential studies, but were not contacted during the gap between the baseline and follow-up studies. The data collected in the original studies, performed between 2008 and 2010, formed the baseline data. In the original studies, exclusion criteria included weight change greater than 2 kg in the preceding 6 months, self-reported regular exercise for periods longer than 60 min/week, treatment with medications known to affect insulin sensitivity or carbohydrate metabolism, known renal, cardiac, or liver disease and current cancer, women planning pregnancy, consumption of more than 20 and 40 g/day alcohol for women and men, respectively, and smoking \>10 cigarettes/day. Type 2 diabetes was defined by medical history or by fasting blood glucose (≥7.0 mmol/L) and/or 2-h blood glucose (≥11.1 mmol/L) following a 75 g oral glucose tolerance test (OGTT), which was performed during screening \[[@B17-jcm-08-00623]\]. Non-diabetic participants from the baseline cohort (*n* = 99, [Figure 1](#jcm-08-00623-f001){ref-type="fig"} (Consort Diagram)) had their interest for participating in a follow-up study gauged by postal mail. Four were of Asian descent, the rest were Caucasian. Of the baseline participants, 25 were uncontactable or living interstate, 12 declined, 3 had a medical condition precluding participation in the follow-up study, 1 was actively losing weight, and 1 had passed away ([Figure 1](#jcm-08-00623-f001){ref-type="fig"}). Fifty-seven individuals were invited to the Clinical Research Facility for a screening visit to assess their medical status, and, if willing, progress to an additional study visit, which included detailed phenotyping, as described below. Sixteen individuals who were screened at follow-up did not progress to the detailed phenotyping study, 7 as they had lost interest and 9 due to medical conditions ([Figure 1](#jcm-08-00623-f001){ref-type="fig"}).

2.2. Baseline and Follow-Up Studies {#sec2dot2-jcm-08-00623}
-----------------------------------

Protocols applied during the baseline and follow-up studies were almost identical, as detailed below.

### 2.2.1. Screening Visit {#sec2dot2dot1-jcm-08-00623}

Participants were invited to the Clinical Research Facility to a screening visit in the morning after an overnight fast. The study included physical examination, weight, height, waist and hip circumference and blood pressure (Omron, Model IA1B, Port Melbourne, Australia) measurements. Fasting blood samples were collected. Physical activity was assessed using the Stanford 7-day activity questionnaires, as described previously \[[@B18-jcm-08-00623]\].

### 2.2.2. Detailed Phenotyping {#sec2dot2dot2-jcm-08-00623}

On a separate day, participants underwent hyperinsulinaemic-euglycaemic clamp and dual-energy X-ray absorptiometry (DXA) to assess insulin resistance and body composition, respectively. Liver fat was assessed by computed tomography (CT) at baseline and, to minimise cumulative radiation exposure, proton magnetic resonance spectroscopy (^1^H-MRS) at follow-up, as detailed below. These are available for the entire baseline cohort (*n* = 99) and for a sub-cohort of the follow-up cohort (*n* = 41, [Figure 1](#jcm-08-00623-f001){ref-type="fig"}).

Participants were instructed to abstain from physical activity and alcohol for 2 days prior to the study day and to arrive to the Clinical Research Facility after an overnight fast. Hyperinsulinaemic-euglycaemic clamp was performed using the same protocols used at the baseline studies \[[@B16-jcm-08-00623],[@B17-jcm-08-00623]\]. Intravenous access was obtained by cannulating each arm at the ante-cubital fossa. One arm was used for obtaining venous blood glucose for monitoring throughout the clamp. The contralateral arm was used for insulin (Actrapid, Novo Nordisk Pharmaceuticals, Baulkham Hills, NSW, Australia) and 25% glucose (Baxter Healthcare, Toongabbie, NSW, Australia) infusion. Insulin was infused at a constant rate, with a supra-physiological concentration chosen to suppress hepatic gluconeogenesis, so that differences in net glucose disposal between groups could be interpreted as differences in peripheral (mainly muscle) glucose disposal. Insulin infusion rate was the same as that used in the baseline studies, 60 \[[@B16-jcm-08-00623]\] or 80 \[[@B17-jcm-08-00623]\] mU/m^2^/min. Glucose was infused at a variable rate to maintain a venous glucose concentration of 4.5--5.5 mmol/L. Insulin resistance (median clamp M-value (M/I)) was expressed in terms of average glucose infusion rate (GIR) obtained from the last 30 min of the clamp (steady state) normalised to fat-free mass (FFM) and steady state serum insulin concentrations (I).

DXA (Lunar Prodigy, GE Healthcare, Chicago, IL, USA) was used to measure total body fat mass and FFM (enCORE software Version 16), the android and gynoid region, and visceral fat (CoreScan software, GE Healthcare) at St Vincent's Clinic Bone Densitometry (Sydney, Australia). Standard fields of view automatically placed by the DXA software included the android (abdominal) and gynoid (hip) regions. The lower margin of the android region was defined by the pelvic cut line and the lateral margins by the arm cut lines. The upper margin was set at a height that is equal to 20% of the distance between the pelvic cut line and the neck cut line. The height of the android region is used to delineate the gynoid area. The upper border is set below the pelvic cut at a distance that is 1.5 times the height of the android region. The height of the gynoid region is twice the height of the android region. The lateral borders are defined by the outer leg cut lines (GE Healthcare Lunar enCORE-based X-ray Bone Densitometer User Manual, 2013). Visceral adipose tissue was determined from the android region by the software algorithm, which corrects total fat mass in the android region for estimated subcutaneous fat, providing visceral adipose tissue volume in cm^3^ (which may be converted to mass using the multiplicative constant 0.94 g/cm^3^).

Liver fat was measured by liver density, an inverse measure of fat content, derived from CT (Gemini GXL, Philips, The Netherlands) during the baseline study. Briefly, liver attenuation values (measured in Hounsfield units \[Hu\]) from a 10 mm axial slice at T12/L1 level were derived. Three regions of interest were measured and averaged (one in the left lobe, two in the right lobe) to calculate the liver attenuation value. ^1^H-MRS was performed at the follow-up studies, using a 1.5-Tesla Ingenia whole-body system (Philips Medical Systems, Best, The Netherlands). Briefly, image-guided, localised ^1^H-MRS were acquired from a voxel of 3.0 × 3.0 × 3.0 cm, with volumes of interest centred within the right lobe of the liver. Subjects lay supine, with spectra acquired using the PRESS (point resolved spectroscopy) technique (TR = 2800 ms, TE = 36 ms, six measurements, 1024 sample points) during respiratory gating. Spectral data were post-processed by magnetic resonance user interface software (jMRUI version 3.0, EU Project) as described \[[@B19-jcm-08-00623]\]. In order to compare the liver fat content gathered in the baseline and follow-up studies using different imaging methods (CT and MRS, respectively), we considered the imaging modalities' correlations with the gold-standard method for defining fatty liver, the histological grading of liver tissue. Normal liver fat content is most commonly defined as macroscopic steatosis in less than 5% of hepatocytes \[[@B20-jcm-08-00623]\]. To define fatty liver, we applied cut-offs derived in the study by Van Werven et al., comparing CT, ^1^H-MRS and liver histology in a similar cohort. In that study of 46 men and women (average body mass index (BMI) 27 kg/m^2^, 59 years of age) fatty liver (\>5% liver fat by histology) correlated to a CT measure of 54.2 Hu (with 74% sensitivity and 70% specificity) and ^1^H-MRS measure of 1.8% (with 91% sensitivity and 87% specificity) \[[@B21-jcm-08-00623]\]. Hence, the presence of excess liver fat accumulation was determined by a liver attenuation value of less than 54.2 Hu at baseline and a liver fat content of greater than 1.8% at follow-up.

2.3. Biochemical Analyses {#sec2dot3-jcm-08-00623}
-------------------------

Whole blood glucose was analysed using a glucose analyser (YSI 2300 Stat Plus, YSI Incorporated Ohio USA, Yellow Springs, OH, USA), and serum insulin was measured using radioimmunoassay (Human Insulin-Specific RIA, Millipore, Burlington, MA, USA). Serum lipid profile was analysed by a spectrophotometric assay (Advia® 2400 Chemistry System \[Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA\]), with low-density lipoprotein (LDL) calculated using the Friedewald equation. Fibroblast growth factor (FGF)-19, FGF-21, total adiponectin, fatty acid-binding protein 4 (FABP4), lipocalin 2 and retinol-binding protein 4 (RBP4) were measured by ELISA (Antibody and Immunoassay service, University of Hong Kong), as previously described \[[@B22-jcm-08-00623]\]. Serum lipid profile and the circulating adipokines were measured in serum samples, from the baseline and follow-up study stored at −80 °C, after the completion of the follow-up study, whereas whole blood glucose was measured in fresh samples when collected, on the baseline and follow-up studies. Serum insulin concentrations were measured in samples batched and stored at −80 °C until analysis, at the end of the baseline and follow-up studies, separately.

2.4. Statistical Analysis {#sec2dot4-jcm-08-00623}
-------------------------

Groupings of the cohort were made using the BMI and M/I value from the baseline data. The Lean group included all individuals with BMI \< 25 kg/m^2^. Those with BMI ≥ 25 kg/m^2^ were categorised as Ob~Res~ if their M/I were below the median M/I value for each gender and Ob~Sen~ if above.

The baseline and follow-up data were analysed to check for homoscedasticity using a Bartlett test \[[@B23-jcm-08-00623]\]. To compare the differences in outcome measures between groups, if the variances across the groups were equal, one-way ANOVA was performed followed by a Tukey--Kramer posthoc test for significance. In the case of unequal variances, Welsh's ANOVA was calculated and the Games--Howell posthoc test \[[@B24-jcm-08-00623]\] used to determine significant differences. In both cases, the significance cutoff was 0.05.

To analyse the changes in the variables as a function of time, the rate of change was determined as $\frac{{Follow} - {up}~{Value}~ - ~{Baseline}~{Value}}{{Time}~{between}~{measurements}}$ for each baseline group. To assess whether the variables for each group changed significantly over time, the values of the changes were tested to see if they were significantly different from zero. A one-sample *t*-test was performed both for all the data (*p*~time~) and for each group. The significance level in the latter case was corrected for multiple comparisons using a Bonferroni correction (significance at *p* ≤ 0.0167), where the significance cutoff of 0.05 was divided by 3, the number of groups. As the change with time data had unequal variances across the groups, Welsh's ANOVA with the Games--Howell posthoc test was used to determine significant differences between the groups (*p*~group~). A Chi-squared test was performed to test the change in liver fat status in the different groups from baseline to follow-up.

Pairwise Spearman correlations between baseline and follow-up values were calculated. Both the correlations with *p* ≤ 0.05 and *p* ≤ 0.01, taking multiple comparisons into account, were determined.

Statistical analyses were implemented in MATLAB (R2018b The Mathworks, Inc. 2018, Natick, MA, USA).

3. Results {#sec3-jcm-08-00623}
==========

3.1. Baseline Characteristics {#sec3dot1-jcm-08-00623}
-----------------------------

The cohort characteristics are described in [Table 1](#jcm-08-00623-t001){ref-type="table"}. Median age in this cohort was 49.8 years (interquartile range (IQR) 22.9, (37.2, 60.0)). When retrospectively grouping the baseline cohort, Ob~Sen~ were significantly younger than Ob~Res~ (*p* = 0.001) and not different from the Lean group (*p* = 0.99). BMI in Ob~Res~ was marginally higher than Ob~Sen~ (*p* = 0.056). Fat-free mass and fat mass were not significantly different between Ob~Sen~ and Ob~Res~ (*p* ≥ 0.24). While fat content in the gynoid region was not different between the overweight/obese groups, fat content in the android region in Ob~Sen~ was intermediate between Lean and Ob~Res~, and a similar observation was noted for visceral adipose tissue volume ([Table 1](#jcm-08-00623-t001){ref-type="table"}). Liver fat measured by CT attenuation index in Ob~Sen~ was intermediate between the higher level measured in Ob~Res~ and lower level measured in the Lean group ([Table 1](#jcm-08-00623-t001){ref-type="table"}).

Blood pressure (systolic and diastolic) and fasting blood glucose measured in Ob~Sen~ were intermediate between that measured in Lean and Ob~Res~ ([Table 1](#jcm-08-00623-t001){ref-type="table"}). Fasting serum triglycerides were significantly higher in both Ob~Sen~ and Ob~Res~ compared with Lean (*p* ≤ 0.002), while fasting HDL-cholesterol and LDL-cholesterol were not significantly different between the groups (*p* ≥ 0.15, [Table 1](#jcm-08-00623-t001){ref-type="table"}).

By design, baseline insulin sensitivity (M/I value) was higher in Ob~Sen~ compared with Ob~Res~. M/I was not different between Lean and Ob~Sen~ and was significantly higher in Lean compared with Ob~Res~ ([Figure 2](#jcm-08-00623-f002){ref-type="fig"}A). Similarly, fasting insulin was significantly lower in Ob~Sen~ versus Ob~Res~, and not different between Lean and Ob~Sen~ ([Figure 2](#jcm-08-00623-f002){ref-type="fig"}B).

Circulating adiponectin was significantly higher and FABP4 lower in Lean compared with Ob~Res~ (*p* ≤ 0.026), and concentrations of these adipokines in Ob~Sen~ were not significantly different from either Lean or Ob~Res~. Other circulating cytokines, including FGF19, FGF21, lipocalin-2 and RBP4, were not significantly different between the groups *(p* ≥ 0.23, [Table 1](#jcm-08-00623-t001){ref-type="table"}).

Self-reported physical activity engagement was not significantly different between the groups (*p* = 0.52, data not shown).

3.2. Follow-Up {#sec3dot2-jcm-08-00623}
--------------

Average follow-up was 5.4 ± 0.1 years (range 4.3--7.6). Of 99 participants at baseline, 57 participated in the follow-up study ([Figure 1](#jcm-08-00623-f001){ref-type="fig"}). On average, individuals lost to follow-up (for all reasons as detailed in [Figure 1](#jcm-08-00623-f001){ref-type="fig"}, *n* = 42) were younger, significantly leaner and metabolically healthier at baseline, with lower blood pressure and a more favorable baseline lipid profile ([Table 2](#jcm-08-00623-t002){ref-type="table"}).

BMI remained statistically indistinguishable between Ob~Res~ and Ob~Sen~ at follow-up (*p* = 0.33, [Table 1](#jcm-08-00623-t001){ref-type="table"}), but, similarly to baseline, visceral fat volume remained lower in Ob~Sen~ compared with Ob~Res~ (*p* = 0.03, [Table 1](#jcm-08-00623-t001){ref-type="table"}). At follow-up, however, the distinction in liver fat content, measured by ^1^H-MRS, between Ob~Sen~ and the Ob~Res~ group was no longer significant (*p* = 0.31, [Table 1](#jcm-08-00623-t001){ref-type="table"}).

Between-group analysis at the follow-up time point revealed that M/I at follow-up in Ob~Sen~ remained significantly higher compared to Ob~Res~, and not different from Lean ([Figure 2](#jcm-08-00623-f002){ref-type="fig"}C). Fasting insulin was not significantly different between Ob~Sen~ and Ob~Res~ at follow-up (*p* = 0.13), but remained lower in Lean compared with Ob~Res~ ([Figure 2](#jcm-08-00623-f002){ref-type="fig"}D).

Systolic and diastolic blood pressure remained significantly lower in Ob~Sen~ and Lean compared with Ob~Res~ (*p* ≤ 0.012), but fasting blood glucose was not significantly different between Ob~Res~ and Ob~Sen~ (*p* = 0.37), only significantly lower in Lean versus Ob~Res~ (*p* = 0.004). HDL-cholesterol was significantly higher in Ob~Sen~ compared with Ob~Res~ (*p* = 0.010), and serum triglycerides were significantly lower in Lean compared with Ob~Res~ (*p* = 0.003), but not different between Ob~Sen~ and either Lean or Ob~Res~ (*p* = 0.070, [Table 1](#jcm-08-00623-t001){ref-type="table"}).

Similarly to baseline, self-reported physical activity engagement was not different between the groups at the follow-up time point (*p* = 0.35, data not shown).

3.3. Change in Anthropometry, Metabolic Health and Insulin Resistance {#sec3dot3-jcm-08-00623}
---------------------------------------------------------------------

We evaluated the change in metabolic parameters with time, by calculating the difference in the values of the measures from baseline to follow-up, normalising for the time elapsed between the baseline and follow-up studies.

### 3.3.1. Body Weight and Fat Content {#sec3dot3dot1-jcm-08-00623}

Surprisingly, BMI (*p*~time~ = 0.24, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}A) and waist circumference (*p*~time~ = 0.17, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}B) did not change significantly over time in this cohort. However, body fat increased significantly over time (*p*~time~ = 0.006, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}C). Other anthropometric and body composition (DXA-derived) variables changed significantly over time, and while none showed a significant difference between groups ([Figure 3](#jcm-08-00623-f003){ref-type="fig"}), in many the significant changes over time were driven by the Ob~Res~ group (as evaluated by one-way *t*-test, Bonferroni-corrected and accepting *p* ≤ 0.0167 as statistically significant). For example, FFM decreased significantly (*p*~time~ = 0.0035, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}D), and the change with time primarily driven by the Ob~Res~ (*p* = 0.0163). Similarly, fat content in the android region increased significantly over time (*p*~time~ = 0.0013, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}E), driven by the Ob~Res~ group (*p* = 0.0087, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}E). Visceral fat volume increased over time (*p*~time~ \< 0.001, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}F), driven by a significant increase in the Ob~Res~ (*p* = 0.0001, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}F). On the other hand, gynoid region mass decreased significantly in the cohort (*p*~time~ \< 0.001), also driven by a decrease in the Ob~Res~ (*p* = 0.0005).

### 3.3.2. Liver Fat {#sec3dot3dot2-jcm-08-00623}

Fatty liver status did not change significantly for any of the groups from baseline to follow-up (Chi-squared test *p* = 0.62, *p* = 0.32 and *p* = 1, for Lean, Ob~Sen~ and Ob~Res~, respectively). There was a larger proportion of Ob~Sen~ compared with Ob~Res~ having a stable absence of fatty liver (56 versus 12%); and a larger proportion of Ob~Res~ compared with Ob~Sen~ having a stable presence of fatty liver (76 versus 22%, [Table 3](#jcm-08-00623-t003){ref-type="table"}).

### 3.3.3. Cardiovascular Health Markers and Insulin Resistance {#sec3dot3dot3-jcm-08-00623}

Systolic blood pressure increased overall (*p*~time~ = 0.0003, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}G), and significantly in Ob~Res~ (*p* = 0.0039), while diastolic blood pressure, whilst increasing across the whole cohort (*p*~time~ = 0.0003), did not change significantly (with Bonferroni correction) within any of the groups ([Figure 3](#jcm-08-00623-f003){ref-type="fig"}H). Fasting glucose (*p*~time~ = 0.42, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}I), HDL-cholesterol (*p*~time~ = 0.88), LDL-cholesterol (*p*~time~ = 0.75), triglycerides (*p*~time~ = 0.73) and total cholesterol (*p*~time~ = 0.78) did not change significantly over time in this cohort (with little change in the number of individuals treated with lipid-lowering medication, [Table 1](#jcm-08-00623-t001){ref-type="table"}). Similarly, M/I (*p*~time~ = 0.40, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}J) and fasting insulin (*p*~time~ = 0.95, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}K) did not change significantly over time. As body FFM decreased significantly in Ob~Res~ ([Figure 3](#jcm-08-00623-f003){ref-type="fig"}D, *p*~ObRes~ = 0.0163), we calculated a new variable GIR normalised to circulating steady state insulin, but not normalised to FFM. Similar to M/I, this new variable GIR/I did not change significantly over time in this cohort (*p*~time~ = 0.31, [Figure 3](#jcm-08-00623-f003){ref-type="fig"}L).

3.4. Correlates of Follow-Up Insulin Resistance {#sec3dot4-jcm-08-00623}
-----------------------------------------------

Baseline and follow-up anthropometry, metabolic markers and glucose control, including insulin resistance, correlated tightly ([Figure 4](#jcm-08-00623-f004){ref-type="fig"}). The best correlate of follow-up insulin resistance (M/I) was baseline M/I, followed by inverse correlations with central adiposity, measured by visceral fat volume and waist circumference, fat-free mass, BMI, diastolic blood pressure, fasting serum insulin and liver fat ([Table 4](#jcm-08-00623-t004){ref-type="table"}).

4. Discussion {#sec4-jcm-08-00623}
=============

In this study, we followed the change in insulin resistance, metabolic health and body fat composition in individuals with overweight and obesity over a 4.3--7.6 year period. Insulin resistance did not change significantly over time in this cohort, and, similarly to the Lean group, Ob~Sen~ maintained their superior insulin sensitivity relative to Ob~Res~ at follow-up. However, it is important to note that when we retrospectively grouped individuals who were overweight and obese into insulin-sensitive and insulin-resistant sub-groups, the Ob~Sen~ group was significantly younger than the Ob~Res~ group. This is consistent with large cohort epidemiological studies, following the change in metabolic health in individuals who were overweight and obese, reporting that metabolically healthy obesity is rare in older individuals, and that the majority of individuals who are overweight and obese are likely to acquire the metabolic syndrome over time, at ages ranging from early 50s to late 80s \[[@B7-jcm-08-00623],[@B8-jcm-08-00623],[@B9-jcm-08-00623],[@B10-jcm-08-00623],[@B11-jcm-08-00623],[@B12-jcm-08-00623],[@B13-jcm-08-00623],[@B14-jcm-08-00623]\].

Two consistent predictors of maintenance of metabolic health in obesity across previous large cohort longitudinal studies were younger age, and a more peripheral fat distribution \[[@B9-jcm-08-00623],[@B15-jcm-08-00623]\]. In our study, we found that insulin-resistant individuals who were overweight/obese were more susceptible than the insulin-sensitive groups to adverse deposition of abdominal adiposity (android region and visceral fat) and loss of gynoid region and fat-free mass. This was despite no change in BMI or waist circumference over time. Insulin resistance in obesity is strongly associated with muscle mass loss in the elderly, termed "sarcopenic obesity" \[[@B25-jcm-08-00623]\]. In a large cohort of non-obese and obese individuals, Lee and colleagues reported that the proportion of muscle mass (appendicular muscle) to body weight was significantly elevated in men with obesity who remained metabolically healthy over 4 years \[[@B26-jcm-08-00623]\]. The same was found in men and women who were non-obese, but interestingly, not in women with obesity \[[@B26-jcm-08-00623]\]. Skeletal muscle is the primary tissue determining whole body insulin resistance. Fat-free mass loss was observed only in the Ob~Res~ sub-cohort. To our surprise, this was not reciprocated with further deterioration in insulin resistance measured by either hyperinsulinemic-euglycemic clamp or fasting insulin. This may be explained by these methodologies' lowest detection limits, or by the fact that the FFM loss was not substantial enough to affect whole body insulin resistance.

We and others have suggested that a low degree of liver steatosis is a strong feature of insulin sensitivity in obesity \[[@B27-jcm-08-00623]\]. Indeed, liver fat content measured by CT in Ob~Sen~ in the present study was intermediate, higher compared with Lean and lower compared with Ob~Res~, confirming previous observations \[[@B2-jcm-08-00623],[@B28-jcm-08-00623]\]. Presence or absence of fatty liver over time in the present study did not change for the majority of participants, with more Ob~Sen~ having a stable absence of fatty liver than Ob~Res~ and more Ob~Res~ having a stable presence of fatty liver than Ob~Sen~. At follow-up, the significant distinction in liver fat content between Ob~Sen~ and the Ob~Res~ was lost. We speculate that this relates to the smaller sample size at follow-up, and possibly inadequate statistical power, or the relatively short-term follow-up. Healthy adipose tissue expansion and better capacity to upregulate lipogenesis in adipose tissue \[[@B2-jcm-08-00623],[@B29-jcm-08-00623],[@B30-jcm-08-00623]\] are thought to explain protection against lipid spill-over to the liver and the muscle in insulin-sensitive obesity. While these findings should be interpreted cautiously due to the different modalities used to evaluate liver fat at baseline and follow-up, the maintenance of the baseline liver fat status by the majority of participants is consistent with the lack of significant change in insulin resistance over time in the present study.

Interestingly, the best correlate of future insulin resistance was insulin resistance measured at baseline, suggesting that insulin resistance is an intrinsic characteristic. Other strong predictors were visceral fat, waist circumference, BMI and liver fat. Higher waist circumference \[[@B15-jcm-08-00623]\] and visceral fat area \[[@B11-jcm-08-00623]\] have been previously suggested to predict loss of metabolic health in obesity over time. Here, we complement these findings and maintain that ectopic deposition of fat in the liver at younger age predicts future insulin resistance.

The strengths of our study include the detailed phenotyping using gold-standard measurement of insulin resistance and body fat composition and distribution, and the paired design. A major limitation is the loss of participants to follow-up and the small sample size at follow-up. Furthermore, bias relating to populations likely to volunteer to studies may have affected the findings and may explain the failure to detect changes in body weight over time, contrary to expectations. Lastly, different modalities were used to measure liver fat at baseline and follow-up and the cut-offs used to define fatty liver status were adopted from a different study population, which may have influenced the findings.

5. Conclusions {#sec5-jcm-08-00623}
==============

Our findings suggest that insulin resistance at an older age strongly aligns with unfavourable abdominal fat distribution and liver fat measured at a younger age. Furthermore, insulin resistance at a young age predisposes to adverse metabolic outcomes and fat-free mass loss, suggesting that maintenance of body fat-free mass should be encouraged to promote healthy aging in obesity.
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![Study Flow (Consort Diagram). \* Medical conditions precluding from follow-up screening included bowel cancer, mitral valve repair and cardiac arrhythmia, chronic lymphocytic lymphoma, breast cancer on letrozole, non-Hodgkin's lymphoma, sleeve gastrectomy and trying to conceive. \*\* Medical conditions precluding from detailed phenotyping included tetralogy of fallot, venous thrombotic disease, venous access difficulty (axillary lymph node clearance), iron deficiency anemia of uncertain cause, significant coronary artery disease (requiring stenting, coronary artery bypass grafting and aspirin therapy), immunosuppressant therapy for psoriatic arthritis, renal failure and significant hypertension (189/109 mmHg), severe untreated autoimmune urticaria, excessive alcohol consumption (\>20 g/day for a female participant) with paroxysmal atrial fibrillation.](jcm-08-00623-g001){#jcm-08-00623-f001}

![Insulin resistance at baseline and follow-up in Lean and overweight/obese insulin-resistant (Ob~Res~) and insulin-sensitive (Ob~Sen~) individuals. Insulin resistance (median clamp M-value (M/I), **A** and **C**) and fasting serum insulin (**B** and **D**) measured at baseline and follow-up, respectively, in Lean and overweight/obese individuals. Data are individual data points with median and interquartile range (IQR). Welsh's ANOVA was calculated and the Games--Howell posthoc test was used to determine significant differences. The *p* for the Welsh's ANOVA is indicated at the top of the plots, with the significance between groups indicated.](jcm-08-00623-g002){#jcm-08-00623-f002}

###### 

Change in anthropometry, metabolic health and glucose regulation markers from baseline to follow-up in Lean and overweight/obese insulin-resistant and insulin-sensitive individuals. Annual change in body mass index (BMI) (**A**), waist circumference (**B**), body fat (**C**), fat-free mass (**D**), android fat (**E**), visceral fat (**F**), systolic (**G**) and diastolic (**H**) blood pressure, fasting blood glucose (**I**), M/I (**J**), fasting insulin (**K**) and glucose infusion rate (GIR)/I (**L**) in Lean and overweight/obese individuals. Change (IQR) in variables as a function of time, for each of the baseline groups: Lean, Ob~Res~ and Ob~Sen~. The change was determined as $\frac{\text{Follow-up}~{Value} - {Baseline}~{Value}}{{Time}~{between}~{measurements}}$. Differences between the groups were assessed using a Welsh's ANOVA (accounting for unequal variances in the change data) with the Games--Howell posthoc test. The p~group~ value is indicated at the top of each plot for each variable. Changes over time for the cohort were assessed using a one-sample *t*-test for difference from zero with *p*~time~ also indicated at the top of each plot. The *p* values for the differences from zero for each individual group are shown at the bottom of each plot. A correction for multiple comparisons (Bonferroni) was applied with significance set at *p* ≤ 0.0167. Data are individual values of change (IQR). Abbreviations: WC, waist circumference; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose.

![](jcm-08-00623-g003a)

![](jcm-08-00623-g003b)

![Associations between baseline and follow-up metabolic health, anthropometry and body composition. Pairwise Spearman coefficients were calculated and the *p* values determined. If 0 ≤ *p* \< 0.05, then the R value of the correlation is shown in color, with upper triangle indicating 0 ≤ *p* \< 0.05, and lower triangle indicating 0 ≤ *p* \< 0.01 for the correlation. The correlation coefficient is indicated using the color scale.](jcm-08-00623-g004){#jcm-08-00623-f004}
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###### 

Characteristics of the cohort at baseline and follow-up.

                                                               Baseline           Follow-Up                                                                                                   
  ------------------------------------------------------------ ------------------ ------------------ ------------------ -------------- ------------------ ---------------- ------------------ --------------
  N (M/F)                                                      42 (20/22)         30 (15/15)         27 (12/15)                        17 (11/6)          20 (11/9)        20 (8/12)          
  Age (years)                                                  45.6 ± 1.9 ^c^     45.2 ± 2.3 ^c^     57.7 ± 2.4 ^a,b^   **0.00 ^1^**   54.6 ± 2.7 ^c^     54.2 ± 2.4 ^c^   63.4 ± 2.4 ^a,b^   **0.01 ^1^**
  Weight (kg)                                                  64.4 ± 2.0 ^b,c^   85.1 ± 2.3 ^a^     91.0 ± 2.4 ^a^     **0.00 ^1^**   64.4 ± 3.4 ^b,c^   89.5 ± 3.1 ^a^   92.0 ± 3.1 ^a^     **0.00 ^1^**
  BMI (kg/m^2^)                                                22.2 ± 0.6 ^b,c^   28.9 ± 0.7 ^a^     32.0 ± 0.7 ^a^     **0.00 ^1^**   22.8 ± 1.0 ^b,c^   29.9 ± 0.9 ^a^   32.0 ± 0.9 ^a^     **0.00 ^1^**
  Waist circumference (cm)                                     80 ± 1 ^b,c^       99 ± 2 ^a^         106 ± 2 ^a^        **0.00 ^1^**   83 ± 3 ^b,c^       103 ± 2 ^a^      107 ± 2 ^a^        **0.00 ^1^**
  Systolic blood pressure (mmHg)                               114 ± 2 ^b,c^      121 ± 2 ^a,c^      134 ± 3 ^a,b^      **0.00 ^1^**   124 ± 4 ^c^        127 ± 4 ^c^      143 ± 4 ^a,b^      **0.00 ^1^**
  Diastolic blood pressure (mmHg)                              71 ± 1 ^b,c^       76 ± 1 ^a,c^       86 ± 2 ^a,b^       **0.00 ^1^**   79 ± 3 ^c^         80 ± 3 ^c^       91 ± 3 ^a,b^       **0.00 ^1^**
  Fasting blood glucose (mmol/L)                               4.5 ± 0.1 ^b,c^    4.7 ± 0.1 ^a,c^    5.1 ± 0.1 ^a,b^    **0.00 ^1^**   4.5 ± 0.1 ^c^      4.8 ± 0.1        5.1 ± 0.1 ^a^      **0.00 ^1^**
  Total body fat mass (%)                                      29 ± 1 ^b,c^       38 ± 1 ^a^         41 ± 1 ^a^         **0.00 ^1^**   31 ± 2 ^c^         40 ± 2           42 ± 2 ^a^         **0.00 ^1^**
  Android fat mass (% of total android mass)                   26 ± 1 ^b,c^       42 ± 1 ^a,c^       47 ± 1             **0.00 ^1^**   29 ± 3 ^b,c^       45 ± 3 ^a^       48 ± 2 ^a^         **0.00 ^1^**
  Gynoid fat mass (% of total gynoid mass)                     33 ± 1 ^b,c^       39 ± 2 ^a^         41 ± 2             **0.00 ^1^**   34 ± 3 ^c^         41 ± 3           42 ± 2 ^a^         **0.02 ^1^**
  Visceral adipose tissue (cm^3^)                              358 ± 110 ^b,c^    1123 ± 129 ^a,c^   1962 ± 13 ^a,b^    **0.00 ^1^**   593 ± 293 ^c^      1289 ± 307 ^c^   2370 ± 229 ^a,b^   **0.00 ^1^**
  Liver fat \*^\#^                                             60 ± 2 ^b,c^       56 ± 2 ^a,c^       43 ± 2 ^a,b^       **0.00 ^1^**   1.4 ± 2.2 ^c^      4.2 ± 2.3        8.6 ± 1.8 ^a^      **0.00 ^1^**
  Total cholesterol (mmol/L) ^2^                               4.3 ± 0.2          4.8 ± 0.2          4.7 ± 0.2          **0.04**       5.1 ± 0.3          5.1 ± 0.3        4.6 ± 0.2          0.30
  Triglycerides (mmol/L) ^2^                                   0.9± 0.1 ^b,c^     1.3 ± 0.1 ^a^      1.9 ± 0.2 ^a^      **0.00 ^1^**   1.1 ± 0.2 ^c^      1.3 ± 0.2        1.8 ± 0.1 ^a^      **0.00 ^1^**
  HDL-cholesterol (mmol/L) ^2^                                 1.3 ± 0.1          1.3 ± 0.1          1.2 ± 0.1          0.63           1.6 ± 0.1 ^c^      1.4 ± 0.1 ^c^    1.2 ± 0.1 ^a,b^    **0.00 ^1^**
  LDL-cholesterol (mmol/L) ^2^                                 2.6 ± 0.1          2.9 ± 0.2          2.7 ± 0.2          0.15           3.0 ± 0.2          3.1 ± 0.2        2.6 ± 0.2          0.34
  Adiponectin (mg/L)                                           28.6 ± 3.1 ^c^     23.8 ± 2.9         17.4 ± 2.9 ^a^     **0.01 ^1^**   27.7 ± 2.8         23.8 ± 2.7       18.7 ± 2.6         0.07
  FABP4 (µg/L)                                                 12.5 ± 5.5 ^c^     18.7 ± 5.0         34.1 ± 4.9 ^a^     **0.01 ^1^**   13.9 ± 6.6         17.0 ± 6.0       32.2 ± 5.7         0.08
  FGF19 (ng/L)                                                 149 ± 37           107 ± 33           131 ± 32           0.70           102 ± 26           110 ± 26         112 ± 24           0.96
  FGF21 (ng/L)                                                 156 ± 53           143 ± 46           240 ± 40           0.23           151 ± 45           176 ± 35         191 ± 32           0.77
  Lipocalin-2 (µg/L)                                           104 ± 11           93 ± 10            83 ± 10            0.37           114 ± 23           82 ± 22          79 ± 21            0.48
  RBP4 (mg/L)                                                  3.0 ± 0.5          2.3 ± 0.5          2.5 ± 0.5          0.60           2.8 ± 0.4          2.6 ± 0.4        2.1 ± 0.4          0.38
  Participants treated with anti-hypertensive medication (n)   1                  2                  8                                 1                  0                4                  
  Participants treated with lipid lowering medication (n)      0                  3                  7                                 1                  3                6                  

Data are mean ± standard error of the mean (SEM). Significance was tested using one-way Analysis of Variance (significant values highlighted in bold) with Games--Howell post hoc analyses. ^a^ mean is significantly different to Lean, *p* \< 0.05; ^b^ mean is significantly different to Ob~Sen~, *p* \< 0.05; ^c^ mean is significantly different to Ob~Res~, *p* \< 0.05. ^1^ Where the homogeneity of variances assumption was violated, the Welch statistic was used with Games--Howell post hoc. \* Baseline based on CT attenuation (Hu) and follow-up based on ^1^H-MRS (%). ^\#^ Liver attenuation by CT is an inverse correlate of liver fat content. ^2^ Data logged prior to statistical analyses. Abbreviations: FGF, fibroblast growth factor; FABP4, fatty-acid binding protein 4; RBP4, retinol-binding protein 4.

jcm-08-00623-t002_Table 2

###### 

Baseline characteristics of participants who were lost to follow-up versus those who were studied.

  Baseline Characteristic           Not Studied   Studied      *p* Value
  --------------------------------- ------------- ------------ --------------
  N (M/F)                           42 (20/22)    57 (27/30)   **0.00 ^1^**
  Age (years)                       44.4 ± 2.0    52.1 ± 1.7   **0.00 ^1^**
  BMI (kg/m^2^)                     25.2 ± 0.8    28.1 ± 0.7   **0.00 ^1^**
  Waist circumference (cm)          88 ± 2        96 ± 2       **0.00 ^1^**
  Systolic blood pressure (mmHg)    117 ± 2       125 ± 2      **0.01 ^1^**
  Diastolic blood pressure (mmHg)   75 ± 2        78 ± 1       **0.04 ^1^**
  Fasting blood glucose (mmol/L)    4.5 ± 0.1     4.8 ± 0.1    **0.00 ^1^**
  Fasting insulin (mU/L)            11.7 ± 1.1    14.4 ± 0.9   **0.03 ^1^**
  Total cholesterol (mmol/L) ^2^    4.1 ± 0.2     4.9 ± 0.1    **0.00 ^1^**
  Triglycerides (mmol/L) ^2^        1.1 ± 0.1     1.5 ± 0.1    **0.01 ^1^**
  HDL-cholesterol (mmol/L) ^2^      1.1 ± 0.1     1.4 ± 0.0    **0.00 ^1^**
  LDL-cholesterol (mmol/L) ^2^      2.5 ± 0.1     2.9 ± 0.1    **0.02 ^1^**

Data are mean ± SEM. ^1^ Where the homogeneity of variances assumption was violated, the Welch statistic was used. Significance was tested using one-way Analysis of Variance (significant values highlighted in bold). ^2^ Data logged prior to statistical analyses. Abbreviations: HDL: high-density lipoprotein, LDL: low-density lipoprotein.

jcm-08-00623-t003_Table 3

###### 

Presence of fatty liver at baseline and follow-up in Lean, Ob~Sen~ and Ob~Res~.

  --------------------------------------------------------------------
  Presence of Fatty Liver\        Study Group              
  (Baseline to Follow-Up) \*                               
  ------------------------------- ------------- ---------- -----------
  Stable Absence (*n* = 14)       7 (64%)       5 (56%)    2 (12%)

  Gain of fatty liver (*n* = 5)   2 (18%)       2 (22%)    1 (6%)

  Loss of fatty liver (*n* = 2)   1 (9%)        0 (0%)     1 (6%)

  Stable Presence (*n* = 16)      1 (9%)        2 (22%)    13 (76%)

  Total (*n* = 37)                11 (100%)     9 (100%)   17 (100%)
  --------------------------------------------------------------------

Paired liver fat measurements were available for a sub-cohort of 37 individuals who had CT and MRS at baseline and follow-up, respectively. \* Presence of fatty liver determined by a CT value of \<54.2 Hu at baseline and MRS \> 1.8% at follow-up, as described by van Werven et al. \[[@B21-jcm-08-00623]\]. Terminology: Stable Absence: Fatty liver absent at baseline and follow-up; Gain of fatty liver: Fatty liver absent at baseline but present at follow-up; Loss of fatty liver: Fatty liver present at baseline but absent at follow-up; Stable Presence: Fatty liver present at baseline and follow-up.

jcm-08-00623-t004_Table 4

###### 

Baseline correlates of follow-up insulin resistance (M/I).

  Baseline Measure                                       R       *p*
  ------------------------------------------------------ ------- -------------------
  M/I                                                    0.76    **1.1 × 10^−07^**
  Visceral fat volume                                    −0.63   **5.7 × 10^−05^**
  Waist circumference                                    −0.63   **5.8 × 10^−05^**
  Fat-free mass                                          −0.53   **0.001**
  BMI                                                    −0.52   **0.001**
  Diastolic blood pressure                               −0.49   **0.003**
  Fasting Insulin                                        −0.50   **0.003**
  Liver attenuation (Hu) \*                              0.49    **0.003**
  Systolic blood pressure                                −0.47   **0.004**
  Fat in the android region (% of total abdominal fat)   −0.46   **0.006**
  Serum triglycerides                                    −0.38   **0.025**
  Serum HDL cholesterol                                  0.36    **0.034**
  Adiponectin                                            0.34    **0.044**
  Fasting blood glucose                                  −0.34   **0.046**
  Age                                                    −0.33   0.052
  FGF21                                                  −0.29   0.126
  FABP4                                                  −0.26   0.149
  Body fat (% whole body mass)                           −0.25   0.154
  Serum LDL                                              0.24    0.163
  Total Cholesterol                                      0.19    0.277
  RBP4                                                   0.06    0.711
  Fasting NEFA                                           0.07    0.714
  Lipocalin−2                                            0.05    0.764
  FGF19                                                  −0.03   0.878
  Fat in the gynoid region (% of total abdominal fat)    −0.02   0.922

Spearman coefficients were calculated. Significant *p* values are bolded; \* Liver attenuation by CT is an inverse correlate of liver fat content.

[^1]: These authors contributed equally to this work.
